NCT03066011

Registry of Patients Treated With Systemic Mold-Active Triazoles

Study Contact:

Study Phase:

Recruitment Status:

COMPLETED

NCT ID:

NCT03066011

Principal Investigator:

Study Type:

OBSERVATIONAL

Official Title:

Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles

Summary

The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).

Eligibility

Inclusion Criteria:

* Patients taking one of the following target drugs at the time of enrollment: isavuconazonium sulfate (ISAV), voriconazole (VORI), posaconazole (POSA).

Exclusion Criteria:

* Currently enrolled in any clinical trial with an investigational antifungal agent. Individuals who subsequently enroll in an investigational antifungal study will be discontinued and data collected up to the time of investigational product will be evaluable.
* Patients who died before entering the study.
* Patients who previously participated in this registry.

Disease(s) and\or Condition(s)

Invasive Fungal Infection

Primary Purpose

Intervention/Treatment

- Type: DRUG
- Name: Isavuconazonium sulfate
- Description: Oral and Intravenous
- Arm Group Labels: Isavuconazonium sulfate Group
- Type: DRUG
- Name: Voriconazole
- Description: Oral and Intravenous
- Arm Group Labels: Voriconazole Group
- Type: DRUG
- Name: Posaconazole
- Description: Oral and intravenous
- Arm Group Labels: Posaconazole Group

Sponsor

Astellas Pharma Global Development, Inc.